Other constitutional aplastic anemia
| Short Descr | Other constitutional aplastic anemia |
| CMS-HCC v22 | 46 - Severe Hematological Disorders |
| CMS-HCC v24 | 46 - Severe Hematological Disorders |
| CMS-HCC v28 | 109 - Acquired Hemolytic, Aplastic, and Sideroblastic Anemias |
| ESRD-HCC v21 | 46 - Severe Hematological Disorders |
| ESRD-HCC v24 | 46 - Severe Hematological Disorders |
| HHS-HCC v07 | 68 - Aplastic Anemia |
| Rx-HCC v08 | 96 - Acquired Hemolytic, Aplastic, and Sideroblastic Anemias |
| Home Health Clinical Group | MMTA_INFECT |
| Home Health Comorbidity Subgroup | Circulatory 2 |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2024-10-01 | Changed | Full Description Changed. |
| 2015-10-01 | Added | Code established |
|
Code
|
Description
|
|---|---|
| DD070ZZ | Beam Radiation of Rectum using Photons <1 MeV |
| No matching codes found | |
|
Code
|
Description
|
|---|---|
| C9113 | Injection, pantoprazole sodium, per vial [deleted] |
| J0640 | Injection, leucovorin calcium, per 50 mg |
| J1320 | Injection, amitriptyline hcl, up to 20 mg |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram |
| J1447 | Injection, tbo-filgrastim, 1 microgram |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg |
| J1570 | Injection, ganciclovir sodium, 500 mg |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
| J2765 | Injection, metoclopramide hcl, up to 10 mg |
| J2820 | Injection, sargramostim (gm-csf), 50 mcg |
| J3485 | Injection, zidovudine, 10 mg |
| J7310 | Ganciclovir, 4.5 mg, long-acting implant |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg |
| J8510 | Busulfan; oral, 2 mg |
| J8530 | Cyclophosphamide; oral, 25 mg |
| J8560 | Etoposide; oral, 50 mg |
| J8600 | Melphalan; oral, 2 mg |
| J8610 | Methotrexate; oral, 2.5 mg |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg |
| J9001 | Injection, doxorubicin hydrochloride, all lipid formulations, 10 mg [deleted] |
| J9015 | Injection, aldesleukin, per single use vial |
| J9040 | Injection, bleomycin sulfate, 15 units |
| J9041 | Injection, bortezomib, 0.1 mg |
| J9042 | Injection, brentuximab vedotin, 1 mg |
| J9045 | Injection, carboplatin, 50 mg |
| J9046 | Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg |
| J9048 | Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg |
| J9049 | Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg |
| J9050 | Injection, carmustine, 100 mg |
| J9060 | Injection, cisplatin, powder or solution, 10 mg |
| J9065 | Injection, cladribine, per 1 mg |
| J9070 | Cyclophosphamide, 100 mg [deleted] |
| J9098 | Injection, cytarabine liposome, 10 mg |
| J9100 | Injection, cytarabine, 100 mg |
| J9120 | Injection, dactinomycin, 0.5 mg |
| J9130 | Dacarbazine, 100 mg |
| J9150 | Injection, daunorubicin, 10 mg |
| J9151 | Injection, daunorubicin citrate, liposomal formulation, 10 mg |
| J9171 | Injection, docetaxel, 1 mg |
| J9181 | Injection, etoposide, 10 mg |
| J9185 | Injection, fludarabine phosphate, 50 mg |
| J9190 | Injection, fluorouracil, 500 mg |
| J9200 | Injection, floxuridine, 500 mg |
| J9206 | Injection, irinotecan, 20 mg |
| J9208 | Injection, ifosfamide, 1 gram |
| J9212 | Injection, interferon alfacon-1, recombinant, 1 microgram |
| J9213 | Injection, interferon, alfa-2a, recombinant, 3 million units |
| J9214 | Injection, interferon, alfa-2b, recombinant, 1 million units |
| J9215 | Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu |
| J9230 | Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg |
| J9245 | Injection, melphalan hydrochloride, not otherwise specified, 50 mg |
| J9250 | Methotrexate sodium, 5 mg [deleted] |
| J9260 | Injection, methotrexate sodium, 50 mg |
| J9263 | Injection, oxaliplatin, 0.5 mg |
| J9265 | Injection, paclitaxel, 30 mg [deleted] |
| J9267 | Injection, paclitaxel, 1 mg |
| J9270 | Injection, plicamycin, 2.5 mg |
| J9280 | Injection, mitomycin, 5 mg |
| J9293 | Injection, mitoxantrone hydrochloride, per 5 mg |
| J9340 | Injection, thiotepa, 15 mg |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg |
| J9360 | Injection, vinblastine sulfate, 1 mg |
| J9370 | Vincristine sulfate, 1 mg |
| J9390 | Injection, vinorelbine tartrate, 10 mg |
| Q0083 | Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit |
| Q0084 | Chemotherapy administration by infusion technique only, per visit |
| Q0085 | Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit |
| Q2017 | Injection, teniposide, 50 mg |
| Q2050 | Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg |
| S0145 | Injection, pegylated interferon alfa-2a, 180 mcg per ml |
| S0148 | Injection, pegylated interferon alfa-2b, 10 mcg |
| S0164 | Injection, pantoprazole sodium, 40 mg [deleted] |
| S2150 | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition |
| S9537 | Home therapy; hematopoietic hormone injection therapy (e.g., erythropoietin, g-csf, gm-csf); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
| No matching codes found | |
|
Code
|
Description
|
|---|---|
| 284.09 | Other constitutional aplastic anemia |
| No matching codes found | |